Anika Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Anika Therapeutics, Inc. (ANIK) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $929.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-29
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $465.00K, a 5.10% decline year-over-year.
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $464.00K, a 19.58% decline year-over-year.
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $499.00K, a 15.28% decline year-over-year.
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $495.00K, a 15.53% decline year-over-year.
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.06M, a 4.14% decline from fiscal 2024.
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $2.15M, a 3.63% decline from fiscal 2023.
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.23M, a 20.59% increase from fiscal 2022.
- Anika Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.85M, a 8.31% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $465.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $929.00K 10-Q · filed 2026-07-29 | $1.43M derived: sum of 3 quarters · filed 2026-07-29 | $1.92M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $464.00K 10-Q · filed 2026-04-30 | $963.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.46M derived: sum of 3 quarters · filed 2026-04-30 | $1.95M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $994.00K derived: sum of 2 quarters · filed 2026-03-03 | $1.48M derived: sum of 3 quarters · filed 2026-07-29 | $2.06M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $495.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $985.00K derived: sum of 2 quarters · filed 2026-07-29 | $1.56M 10-Q · filed 2025-11-05 | $2.15M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | $490.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $1.07M 10-Q · filed 2026-07-29 | $1.66M derived: sum of 3 quarters · filed 2026-07-29 | $2.24M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | $577.00K 10-Q · filed 2026-04-30 | $1.17M derived: sum of 2 quarters · filed 2026-04-30 | $1.75M derived: sum of 3 quarters · filed 2026-04-30 | $2.16M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $589.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.18M derived: sum of 2 quarters · filed 2026-03-03 | $1.58M derived: sum of 3 quarters · filed 2026-03-03 | $2.15M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $586.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $996.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.56M 10-Q · filed 2025-11-05 | $2.16M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-06-30 | $410.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $975.00K 10-Q · filed 2025-07-30 | $1.57M derived: sum of 3 quarters · filed 2026-03-03 | $2.12M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-03-31 | $565.00K 10-Q · filed 2025-05-09 | $1.16M derived: sum of 2 quarters · filed 2026-03-03 | $1.71M derived: sum of 3 quarters · filed 2026-03-03 | $2.25M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2023-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.15M derived: sum of 2 quarters · filed 2026-03-03 | $1.69M derived: sum of 3 quarters · filed 2026-03-03 | $2.23M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $547.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.09M derived: sum of 2 quarters · filed 2024-11-04 | $1.63M 10-Q · filed 2024-11-04 | $2.16M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-06-30 | $544.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.09M 10-Q · filed 2024-08-08 | $1.61M derived: sum of 3 quarters · filed 2025-03-17 | $2.14M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-03-31 | $542.00K 10-Q · filed 2024-05-08 | $1.07M derived: sum of 2 quarters · filed 2025-03-17 | $1.59M derived: sum of 3 quarters · filed 2025-03-17 | $1.99M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2022-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.05M derived: sum of 2 quarters · filed 2025-03-17 | $1.45M derived: sum of 3 quarters · filed 2025-03-17 | $1.85M 10-K · filed 2025-03-17 | |
| 2022-09-30 | $525.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $919.00K derived: sum of 2 quarters · filed 2023-11-03 | $1.32M 10-Q · filed 2023-11-03 | $1.72M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-06-30 | $394.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $797.00K 10-Q · filed 2023-08-08 | $1.19M derived: sum of 3 quarters · filed 2024-03-15 | $1.59M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-03-31 | $403.00K 10-Q · filed 2023-05-09 | $799.00K derived: sum of 2 quarters · filed 2024-03-15 | $1.20M derived: sum of 3 quarters · filed 2024-03-15 | $1.71M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2021-12-31 | $396.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $796.00K derived: sum of 2 quarters · filed 2024-03-15 | $1.30M derived: sum of 3 quarters · filed 2024-03-15 | $1.71M 10-K · filed 2024-03-15 | |
| 2021-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $907.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.31M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $507.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $912.00K 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $405.00K 10-Q · filed 2022-05-06 | ||||
| 2020-12-31 | $1.53K 10-K · filed 2023-03-16 | $1.53M 10-K · filed 2022-03-11 | |||
| 2019-12-31 | $1.18M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |